• J. Andrew Case

Cell and gene therapies are placing the patient at the center of the supply chain in a vastly new way, with implications for production, financial operations, product ordering, logistics and patient access and support. With these high-value therapies gaining more acclaim and moving from academic treatment centers to community care, their therapeutic and commercial success will be more highly scrutinized.
Read more...